Last updated: May 27, 2026
INGREZZA (valbenazine) Suppliers: Who Manufactures, Supplies, and Licenses the Product and APIs
INGREZZA (valbenazine) is supplied in the US market by Biogen (brand owner) with manufacturing and supply chain centered on Valbenazine drug substance and drug product production under Biogen and its contract manufacturing network. The active ingredient is produced and released through a branded supply chain that includes contract manufacturing organizations (CMOs) and packaging sites supporting Biogen’s commercial distribution obligations.
Because “suppliers” can mean different roles (drug substance, drug product, packaging, distribution, or co-marketing licensing partners), the supplier map for INGREZZA is best expressed by manufacturing functions: drug substance (API) suppliers, drug product manufacturers, and secondary packaging/release sites. However, a complete, accurate supplier list with named manufacturers and facility addresses can only be produced from the drug’s Orange Book/label manufacturing section, US FDA establishment listings, and any publicly indexed CMO disclosures.
Who are the drug substance (API) suppliers for INGREZZA (valbenazine)?
Answer: The API supply chain for valbenazine is handled through Biogen’s controlled manufacturing and release system, which typically uses one or more contract and internal facilities for drug substance production and Quality Unit release.
How to identify valbenazine API suppliers in practice
The highest-yield public sources for API supplier identification are:
- INGREZZA prescribing information (label section: “Manufactured for” and/or “Manufactured by” statements)
- FDA Orange Book listing for INGREZZA (for application-level manufacturer and listed facilities)
- FDA Establishment Registration and Listing (EURL/FEI linkage) for manufacturing/release operations tied to the product’s labeled establishments
API-specific supplier mapping (what investors litigate and license)
For licensing and freedom-to-operate work, the API supplier set matters because:
- API site qualification affects DMF/CTD linkage
- Site-specific compliance impacts batch release timelines
- API changes can trigger comparability, post-approval CMC obligations, and patent “process” exposure
Who manufactures INGREZZA drug product (capsules) for Biogen?
Answer: INGREZZA capsule drug product is manufactured within Biogen’s commercial manufacturing network using either Biogen-owned sites and/or contract manufacturers responsible for dosage-form production, sterilization (if applicable), QC release, and packaging configuration.
Packaging, strength, and release roles
INGREZZA is marketed as capsules with dosing strengths. Supplier responsibility typically splits into:
- Primary packaging (capsule filling and closure)
- Secondary packaging (bottling or unit-of-use packaging)
- Batch release via QCU under the labeled manufacturer entity
Facility-level identification sources
- USPI (US prescribing information) manufacturing lines
- Orange Book “Applicant/Manufacturer” for the application covering the NDA
- FDA inspection history by establishment for the labeled manufacturing firms
What organizations supply INGREZZA to the US market (distribution and commercialization)?
Answer: Commercial supply and distribution are coordinated by Biogen as the marketing authorization holder in the US, with logistics executed through its distribution partners or contract logistics providers tied to Biogen’s distribution network.
Why distributor vs manufacturer matters
- Distributors manage cold-chain or logistics only if required (not a primary determinant for INGREZZA)
- Manufacturers determine CMC comparability and batch release
- Patent and regulatory risk attaches primarily to manufacturing and API supply sites, not logistics providers
Does INGREZZA use multiple suppliers across strengths (40 mg and 80 mg)?
Answer: In mature branded supply chains, strengths can share some upstream steps (API and bulk intermediate) while differing in:
- fill-finish line assignments
- capsule configuration and bottling plans
- packaging lot release timing
A full multi-strength supplier table requires facility naming from the label/Orange Book listings for each strength.
Which contract manufacturing organizations (CMOs) support INGREZZA?
Answer: INGREZZA’s supply chain is expected to include CMOs that handle one or more of:
- drug substance manufacturing
- formulation/bulk mixing
- capsule fill-finish
- packaging and labeling
A named CMO list requires extraction from the manufacturing section of the US prescribing information and/or the Orange Book manufacturer and facility fields for the NDA.
What patent or regulatory constraints affect switching INGREZZA suppliers?
Supplier switching for a branded neuropsychiatric drug is constrained by:
- NDA CMC change controls (scale, site, process changes)
- batch comparability and stability obligations
- control strategy updates under ICH Q5/QbD frameworks
- potential method-of-manufacture process IP considerations (where relevant)
For licensing and generic entry planning, the key question is whether a supplier change triggers new process steps that could intersect with patent claims.
Orange Book status: How does it connect to supplier and manufacturing listings?
Answer: The Orange Book listing ties the NDA to:
- listed patent status (if patents are listed for the drug)
- the approved application
- manufacturer and dosage form entries that can be mapped to manufacturing firms
A complete Orange Book-derived supplier list requires direct extraction of the Orange Book fields for INGREZZA, including the “Applicant/Manufacturer” and dosage form entries.
Supplier Map (Template)
The following table is the structure used in high-stakes diligence. It is not populated with named manufacturers because this requires label/Orange Book/facility extraction.
| Function |
Supplier type |
Named company |
Facility role (API vs drug product vs packaging) |
Primary evidence (label/Orange Book/FDA listing) |
| API |
API manufacturer (DS) |
— |
Drug substance production |
US label + Orange Book + FDA establishment |
| Drug product |
Drug product manufacturer (DP) |
— |
Capsule manufacturing and QC release |
US label + Orange Book |
| Packaging |
Packaging/labeling |
— |
Bottling/unit packaging and labeling |
US label + FDA establishment |
| Commercial supply |
Marketing authorization holder |
Biogen |
Distribution/supply coordination |
US label “Manufactured for”/company details |
| Logistics |
Distributor/3PL |
— |
Shipment and distribution |
Contract logistics records or label references |
Key Takeaways
- INGREZZA supply is organized under Biogen’s controlled commercial manufacturing and release system, with roles split across API supply (drug substance), capsule drug product manufacturing, and packaging/labeling.
- “Supplier” diligence for INGREZZA requires facility-level evidence from US prescribing information and Orange Book manufacturer listings linked to FDA establishment registration.
- Named API and CMO supplier identification cannot be completed to a defensible standard without extracting the label manufacturing statements and Orange Book manufacturer/facility fields for each INGREZZA strength.
FAQs
- What does the INGREZZA label say about “manufactured by” versus “manufactured for,” and which supplier does it identify?
- How do Orange Book “applicant” and “manufacturer” fields differ for INGREZZA, and why does it matter for supplier mapping?
- Which FDA database fields are used to connect an INGREZZA strength to specific manufacturing establishments?
- Do API and drug product suppliers for INGREZZA change with site transfers, and how are CMC changes documented?
- How does supplier switching for INGREZZA affect comparability requirements and potential regulatory review timelines?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). US FDA.
- INGREZZA (valbenazine) Prescribing Information. Biogen.
- FDA Establishment Registration and Listing database. US FDA.
